(Textiles) (tr) to moisten or soak (flax, hemp, jute, etc) to promote bacterial action in order to facilitate separation of the fibres from the woody tissue by beating
[C15: of Germanic origin; related to Middle Dutch reeten, Swedish röta, German rösten; see rot1]
Some of these low-frequency mutations were found in important cancer genes such as mitogen-activated protein kinase 4 (MAP2K4), discoidin domain receptor tyrosine kinase 2 (DDR2), and lysine (K)-specific methyltransferase 2D (KMT2D, also known as MLL2) (see online Supplemental Fig.
Craig Venter Institute (Rockville, MD), Ludwig Institute for Cancer Research, and The Johns Hopkins University School of Medicine identified three novel mutations in two receptor tyrosine kinases in glioblastoma tumors using high throughput sequencing.
Lenvatinib is an oral multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of several different RTKs including VEGFR, FGFR, PDGFRalpha, KIT and RET, involved in angiogenesis and tumor proliferation.
Lenvatinib is an oral multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor receptors (VEGFR), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor receptors (FGFR), the platelet-derived growth factor (PDGF) receptor PDGFRα, KIT and RET that are involved in tumor proliferation.
Poziotinib is a novel, orally administered Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) that inhibits the tyrosine kinase activity of EGFR as well as HER2 and HER4.
The product is a third-generation and irreversible epidermal growth factor receptor tyrosine kinase inhibitor with clinical activity against central nervous system metastases.
announced today that the therapeutic effects of lenvatinib (generic name; VEGF receptor tyrosine kinase inhibitor and multi-kinase inhibitor discovered in-house) on melanoma have been confirmed in one of a series of joint development programs being conducted as part of the company's strategic collaboration with Quintiles (United States).
- The European Commission (EC) has granted a marketing authorisation for the oral receptor tyrosine kinase (RTK) inhibitor Lenvima (lenvatinib), as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.